Literature DB >> 8706020

Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats.

K Takasuna1, T Hagiwara, M Hirohashi, M Kato, M Nomura, E Nagai, T Yokoi, T Kamataki.   

Abstract

Irinotecan hydrochloride (CPT-11), an antitumor camptothecin derivative, causes severe forms of diarrhea clinically. We characterized CPT-11-induced diarrhea histologically and enzymologically and assessed the relationships between intestinal toxicity and the activity of the enzymes that play a key role in the major metabolic pathway of CPT-11 in rats. CPT-11 (60 mg/kg i.v. for 4 days) induced intestinal toxicity characterized by severe chronic diarrhea, loss of body weight, and anorexia. Histological damage was most severe in the cecum. The segmental difference in the degree of the damage showed good correlation with the beta-glucuronidase activity in the contents of the lumen in each case, but not with the intestinal tissue carboxylesterase activity, which converts CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin). Inhibition of the beta-glucuronidase activity in the intestinal microflora by antibiotics (1 mg penicillin and 2 mg streptomycin per ml of drinking water) markedly ameliorated the diarrhea and reduced cecal damage. Analysis of CPT-11 and its metabolites in the feces indicated that antibiotics completely inhibited the deconjugation of the glucuronic conjugate of 7-ethyl-10-hydroxycamptothecin by beta-glucuronidase. It is suggested that CPT-11-induced diarrhea would be attributable to the damage to the cecum, and that the inhibition of the beta-glucuronidase activity in the intestinal microflora is a major protective effect of antibiotics.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8706020

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  85 in total

1.  A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer.

Authors:  Ji-Youn Han; Dae Ho Lee; Sung Young Lee; Chun Gun Park; Hae Young Kim; Eun-A Kim; Sung Min Yoon; Hong Gi Lee; Jin Soo Lee
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

2.  Metabolic pathways of the camptothecin analog AR-67.

Authors:  Jamie Horn; Marta Milewska; Susanne M Arnold; Markos Leggas
Journal:  Drug Metab Dispos       Date:  2010-12-28       Impact factor: 3.922

3.  Kampo medicine "Dai-kenchu-to" prevents CPT-11-induced small-intestinal injury in rats.

Authors:  Motoya Chikakiyo; Mitsuo Shimada; Toshihiro Nakao; Jun Higashijima; Kozo Yoshikawa; Masanori Nishioka; Takashi Iwata; Nobuhiro Kurita
Journal:  Surg Today       Date:  2011-11-10       Impact factor: 2.549

Review 4.  Clinical pharmacokinetics of irinotecan.

Authors:  G G Chabot
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

5.  Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats.

Authors:  Masato Horikawa; Yukio Kato; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

6.  Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.

Authors:  Amita Patnaik; Kyriakos P Papadopoulos; Anthony W Tolcher; Muralidhar Beeram; Saïk Urien; Larry J Schaaf; Sanaa Tahiri; Tanios Bekaii-Saab; François M Lokiec; Keyvan Rezaï; Aby Buchbinder
Journal:  Cancer Chemother Pharmacol       Date:  2013-03-30       Impact factor: 3.333

Review 7.  Developing a metagenomic view of xenobiotic metabolism.

Authors:  Henry J Haiser; Peter J Turnbaugh
Journal:  Pharmacol Res       Date:  2012-08-09       Impact factor: 7.658

8.  Pulmonary metabolism of resveratrol: in vitro and in vivo evidence.

Authors:  Satish Sharan; Swati Nagar
Journal:  Drug Metab Dispos       Date:  2013-03-08       Impact factor: 3.922

9.  Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile.

Authors:  Andrea M Stringer; Rachel J Gibson; Joanne M Bowen; Richard M Logan; Kimberly Ashton; Ann S J Yeoh; Noor Al-Dasooqi; Dorothy M K Keefe
Journal:  Int J Exp Pathol       Date:  2009-10       Impact factor: 1.925

10.  Irinotecan toxicity: genes or intestinal microflora?

Authors:  G Brandi; F de Rosa; G Biasco
Journal:  Br J Cancer       Date:  2009-03-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.